Phase 2
N=31
Memory and Insulin in Early Alzheimer's Disease
Alzheimer's Disease
Bottom Line
View on ClinicalTrials.gov: NCT00581867 ↗Enrolled (actual)
31
Serious AEs
1.7%
Results posted
Jul 2015
Primary outcome: Primary: fMRI Measure of Hippocampal Activation — 36.4; 41.3 percentage of active voxels
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Insulin Aspart (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- All
- Sponsor
- Jeff Burns, MD
- Primary completion
- May 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY fMRI Measure of Hippocampal Activation |
36.4; 41.3 | — |
| SECONDARY Global Cognition |
-.05; -.02 | — |
Summary
To determine which parts of the brain are involved in insulin-related memory improvement in early Alzheimer's disease and cognitively normal older adults.
Eligibility Criteria
Inclusion Criteria
- Patients with Early Alzheimer's disease
Exclusion Criteria
- Patients with Late Alzheimer's disease
Data sourced from ClinicalTrials.gov (NCT00581867). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.